OB:PHOPharmaceuticals
Photocure (OB:PHO): Revenue Forecast to Grow 14.5% Annually Ahead of Profitability Turnaround
Photocure (OB:PHO) remains unprofitable but has managed to reduce its losses at an annual rate of 12.8% over the last five years. Backed by forecasts calling for 103.28% annual EPS growth and 14.5% annual revenue growth, which compares to the Norwegian market’s 2.8%, investors have reason to watch closely as the company is anticipated to turn profitable within three years. With a price-to-sales ratio of 2.8x, lower than both its peer average of 6.5x and the European Pharmaceuticals industry...